Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Ischaemic heart disease
“High take off” ST segments do not carry an adverse prognosis ▸ First described in 1936, this study confirms that early repolarisation (high take-off) is more common in men, blacks (48% v 26% with a normal ECG), and in people who take more exercise (10.4 hours per week of activity v 6.4 hours). It is not associated with any increase in mortality, and patients with this pattern appear to have fewer arrhythmias. The danger lies in this normal variant being interpreted as acute myocardial infarction in the era of 30 minute door-to-needle thrombolysis targets.
Primary angioplasty is better than thrombolysis ▸ A total of 1572 patients with acute myocardial infarction were randomised with angioplasty or accelerated treatment with intravenous alteplase. Among patients who underwent randomisation at referral hospitals, the primary end point of death/myocardial infarction/cerebrovascular accident was reached in 8.5% of the patients in the angioplasty group, as compared with 14.2 % of those in the fibrinolysis group (p = 0.002). Among all patients, the better outcome after angioplasty was driven primarily by a reduction in the rate of reinfarction (1.6% in the angioplasty group v 6.3% in the fibrinolysis group; p < 0.001); no significant differences were observed in the rate of death (6.6% v 7.8%; p = 0.35) or the rate of stroke (1.1% v 2.0%, p = 0.15). Ninety six per cent of patients were transferred from referral hospitals to an invasive treatment centre within two hours. Of note, a recent meta-analysis confirmed significant mortality reduction in addition to the above benefits.
Combined low dose aspirin and ACE inhibitor treatment is not harmful ▸ In patients on angiotensin converting enzyme (ACE) inhibitors for heart failure, treatment included no aspirin in 235 (group 1), a low dose (⩽ 160 mg) in 45 (group 2), and a high dose (⩾ 325 mg) in 64 (group 3). During a mean follow up of 37.6 months, there were 84 (36%) deaths in group 1, 15 (33%) in group 2, and 35 (55%) in group 3. Survival was similar in groups 1 and 2, and significantly (p = 0.009) worse in group 3 compared with groups 1 and 2. After adjusting for potential confounding factors (including treatment, cause of heart disease, age, smoking, and diabetes mellitus), a time dependent multivariate Cox proportional hazards regression analysis showed that the combination of high dose aspirin with an ACE inhibitor was independently associated with the risk of death (hazard ratio (HR) 1.03; p = 0.01) and that the combination of low dose aspirin with an ACE inhibitor was not (HR 1.02; p = 0.18).
Morbidity after CABG: the risk of readmission is greater than 10% ▸ Of 16 325 patients, 2111 (12.9%) were readmitted within 30 days for reasons related to coronary artery bypass graft (CABG) surgery. The most common causes of readmission were postsurgical infection (n = 598 (28%)) and heart failure (n = 331 (16%)). Eleven risk factors were found to be independently associated with higher readmission rates: older age, female sex, African American race, greater body surface area, previous myocardial infarction within one week, and six co-morbidities. This may be an important factor in choosing between CABG and coronary angioplasty if both are suitable.
The CHARM offensive begins ▸ ACE inhibitors have become standard treatment for patients with left ventricular systolic dysfunction. Angiotensin II receptor blockers (ARBs) may be an alternative or a useful additive treatment. Overall, 7601 patients (7599 with data) were randomly assigned candesartan (n = 3803, titrated to 32 mg once daily) or matching placebo (n = 3796), and followed up for at least two years. After an average of > 3 years follow up, 23% patients in the candesartan and 25% in the placebo group died (unadjusted HR 0.91, p = 0.055; covariate adjusted HR 0.90, p = 0.032), with fewer cardiovascular deaths (18% v 20%, unadjusted HR 0.88, p = 0.012; covariate adjusted HR 0.87, p = 0.006) and hospital admissions for chronic heart failure (20% v 24%, p < 0.0001) in the candesartan group. It did not matter if the ejection fraction was < 40% or not, nor if they were already on ACE inhibitors.
High dose simvastatin reduces arterial wall thickness in more than two thirds of the patients ▸ After a washout period of six weeks, all patients with familial hypercholesterolaemia (FH) started monotherapy with simvastatin, 80 mg/day, for two years. The primary end point was the change (in mm) of the mean combined far wall intima/media thickness (IMT) of predefined carotid and femoral arterial segments at two years. Mean (SD) combined baseline IMT was 1.07 (0.23) mm. After treatment with simvastatin for two years, this IMT decreased by a mean of 0.081 mm (95% confidence interval (CI) −0.109 to −0.053; p < 0.001), with its largest reduction in the femoral artery (−0.283 mm; p < 0.001). An actual decrease of combined IMT was seen in 69.8% of all patients. Furthermore, patients with FH who were treated with both statin and antihypertensive medication experienced a significantly greater benefit in terms of IMT reduction.
Eplerenone is better tolerated than amlodipine ▸ A total of 269 patients older than 50 years with systolic hypertension were randomised to either eplerenone 50 mg once daily (an aldosterone antagonist), or amlodipine 2.5 mg once daily, and titrated to a maximum 200 mg eplerenone or 10 mg amlodipine. Patients were followed up for 24 weeks. Quality of life questionnaires (SF-36 health survey) and a symptom distress index were administered at randomisation and 24 weeks after starting treatment. The systolic blood pressure response to eplerenone and amlodipine did not differ (eplerenone −20.5 mm Hg and amlodipine −20.1 mm Hg). There was an overall significant treatment effect on symptom distress in favour of eplerenone (p = 0.03). Indeed, the symptom distress index showed significant worsening distress in 36 of 71 symptoms in the amlodipine arm and none in the eplerenone arm.
N-acetyl cysteine should be given to patients with renal impairment before angiography ▸ Contrast nephropathy can be defined by an increase in serum creatinine of at least 44.2 µmol/l or of 25% from baseline values 48 hours after administration of radiocontrast media. Seven trials including 805 patients were eligible for meta-analysis. Overall incidence of contrast nephropathy varied between 8–28%. Compared with periprocedural hydration alone, administration of acetylcysteine and hydration significantly reduced the relative risk of contrast nephropathy by 56% (relative risk (RR) 0.435, p = 0.02) in patients with chronic renal insufficiency. Meta-regression revealed no significant relation between the relative risk of contrast nephropathy and the volume of radiocontrast media administered or the degree of chronic renal insufficiency before the procedure.
Ultrasound guidance of CVP line placement is safe and cost neutral ▸ Doppler ultrasound guidance to place central venous pressure (CVP) lines would logically be safer as one can see where the needle is going. Compared with the landmark method, real time two dimensional ultrasound guidance for cannulating the internal jugular vein in adults was associated with a significantly lower failure rate both overall (RR 0.14, 95% CI 0.06 to 0.33) and on the first attempt (RR 0.59, 95% CI 0.39 to 0.88). Doppler guidance does not appear to give significant advantage over blind procedures. An analysis of 18 trials suggested a cost saving of £2000 per 1000 procedures due to reduced complications and presumed time savings for medical staff.
Stroke risk in AF can be quantified ▸ Previous calculations for stroke risk in atrial fibrillation (AF) have been developed from the trials of aspirin and warfarin treatment. Given that warfarin works, giving patients the absolute risk of stroke may help them in deciding on warfarin treatment. An excel sheet to allow risk calculation is available (http://www.nhlbi.nih.gov/about/framingham/stroke.htm). Using follow up data on a cohort of patients in the Framingham study, of 868 eligible individuals with new onset AF, 705 were not treated with warfarin at baseline and were used in the derivation of the risk scores. During a mean follow up of 4.0 years free of warfarin use, stroke alone occurred in 83 participants and stroke or death occurred in 382 participants. A risk score for stroke was derived that included the following risk predictors: advancing age, female sex, increasing systolic blood pressure, prior stroke or transient ischemic attack, and diabetes. With the risk score, 14.3% of the cohort had a predicted five year stroke rate ⩽ 7.5% and 30.6% of the cohort had a predicted five year stroke rate ⩽ 10%. Actual stroke rates in these low risk groups were 1.1 and 1.5 per 100 person-years, respectively.
Amlodipine in haemochromatosis? ▸ Iron overload cardiomyopathy, resulting from secondary iron overload disorders and in primary haemochromatosis, is responsible for considerable cardiovascular morbidity and mortality on a global scale. Myocardial injury is the major determinant of survival in patients with secondary iron overload, and also occurs in patients with primary haemochromatosis. A common feature of cells susceptible to iron overload, such as cardiac myocytes, pancreatic β cells, and anterior pituitary cells, is the large number and activity of L type voltage dependent Ca2+ channel (LVDCCs). To assess the role of LVDCCs in cardiac iron uptake, these investigators studied the impact of specific LVDCC blockers (amlodipine and verapamil) and cardiac specific overexpression of LVDCCs on iron overload cardiomyopathy in a mouse. Treatment with amlodipine and verapamil at therapeutic levels inhibited the LVDCC current in cardiomyocytes, attenuated myocardial iron accumulation and oxidative stress, improved survival, prevented hypotension, and preserved heart structure and function.
American Journal of Medicine; American Journal of Physiology: Heart and Circulatory Physiology; Annals of Emergency Medicine; Annals of Thoracic Surgery; Archives of Internal Medicine; BMJ; Chest; European Journal of Cardiothoracic Surgery; Lancet; JAMA; Journal of Clinical Investigation; Journal of Diabetes and its Complications; Journal of Immunology; Journal of Thoracic and Cardiovascular Surgery; Nature Medicine; New England Journal of Medicine; Pharmacoeconomics; Thorax
Dr Diana Gorog, Dr Akhil Kapur, Dr Masood Khan, Dr Pipin Ko, Dr Vias Markides, Dr Oliver Segal, Dr Andrew Sharp, Dr Tom Wong